Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

Clinical outcome post-progression to first-line triplet chemotherapy (CT) plus bevacizumab (FIr-B/FOx) was evaluated in metastatic colorectal cancer (MCRC) patients (pts). Second-line treatment was selected according to fitness, KRAS genotype, previous efficacy and safety. Efficacy was evaluated and...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
פורמט: Artigo
שפה:Inglês
יצא לאור: D.A. Spandidos 2013
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3867368/
https://ncbi.nlm.nih.gov/pubmed/24247407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2013.2179
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים